Michael Cookson to Enzyme Inhibitors
This is a "connection" page, showing publications Michael Cookson has written about Enzyme Inhibitors.
Connection Strength
0.064
-
Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials. 2007 Nov; 28(6):763-9.
Score: 0.064